Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2022-08-10 00:00:00 ET · period of report 2022-08-09 · accession 0000899243-22-028248 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2022-08-10	2022-08-09	VRTX	Tatsis Ourania	EVP, Chief Reg, Quality Off	S - Sale	$298.97	-1,400	47.2K	-3%	-$418.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-08-09	S	D	74	$301.67	46,090	D	—	—
2	Common	Common Stock	2022-08-09	S	D	283	$299.79	46,236	D	—	—	(F6) Open market sales reported on this line occurred at a weighted average price of $299.79 (range $299.44 to $300.33). (F3) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
3	Common	Common Stock	2022-08-09	S	D	72	$300.64	46,164	D	—	—
4	Common	Common Stock	2022-08-09	S	D	679	$298.77	46,519	D	—	—	(F5) Open market sales reported on this line occurred at a weighted average price of $298.77 (range $298.29 to $299.19). (F3) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
5	Common	Common Stock	2022-08-09	S	D	292	$297.54	47,198	D	—	—	(F4) Open market sales reported on this line occurred at a weighted average price of $297.54 (range $297.00 to $297.80). (F3) Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F1) Includes 134 shares previously purchased under the issuer's Employee Stock Purchase Plan.